APhA OTC guide
This article was originally published in The Tan Sheet
Executive SummaryThirteenth edition of the Handbook of Nonprescription Drugs "emphasizes patient assessment, triage, self-care options, product evaluation and comparison, patient counseling and evaluation of patient outcomes," American Pharmaceutical Association says. Book's features include section on alternative remedies where applicable, tables of major trade name products, treatment algorithms and case studies; appendices include FDA pregnancy risk categories for selected OTCs, supplements. Handbook, which last was updated in 2000, can be purchased from APhA for $135...
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.